AirXpanders, Inc. (ASX: AXP), a medical device company focused on the design, manufacture, sale and distribution of the AeroForm(R) Tissue Expander System, today announced that the Company has retained Cowen as an independent financial advisor to assist in exploring financial and strategic alternatives. With Cowen’s assistance, the Company will continue to evaluate opportunities to explore a wide range of financial and strategic alternatives, including a capital raise, that could enhance stockholder value and enable the Company to continue serving other important constituencies, including patients and physicians.
About AirXpanders:
Founded in 2005, AirXpanders, Inc. (www.airxpanders.com) designs, manufactures and markets innovative medical devices to improve breast reconstruction. The Company’s AeroForm Tissue Expander System, is used in patients undergoing two-stage breast reconstruction following mastectomy. Headquartered in San Jose, California, AirXpanders’ vision is to be the global leader in reconstructive surgery products and to become the standard of care in two-stage breast reconstruction. AirXpanders is a publicly listed company on the Australian Securities Exchange under the symbol “AXP.” AeroForm was granted U.S. FDA de novo marketing authorization in 2016, subsequent U.S. market clearance in 2017, first CE mark in Europe in 2012 and is currently licensed for sale in Australia.
About Cowen
Cowen Inc. (“Cowen”) is a diversified financial services firm that operates through two business segments: a broker dealer and an investment management division. Cowen’s broker dealer division offers investment banking services, equity and credit research, sales and trading, prime brokerage, global clearing and commission management services. Cowen’s investment management segment offers actively managed alternative investment products. Cowen Inc. focuses on delivering value-added capabilities to clients in order to help them outperform. Founded in 1918, the firm is headquartered in New York and has offices worldwide.
